144 related articles for article (PubMed ID: 22740889)
1. Impact of post-operative hormone replacement therapy on life quality and prognosis in patients with ovarian malignancy.
Li L; Pan Z; Gao K; Zhang W; Luo Y; Yao Z; Liang X; Tang B; Li QQ
Oncol Lett; 2012 Jan; 3(1):244-249. PubMed ID: 22740889
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between hormone therapy in women with ovarian malignancy and prognosis].
Li L; Pan ZM; Chen XQ; Gao K; Zhang W; Luo Y; Yao ZQ; Liang XQ; Huang W; Yao DS
Zhonghua Fu Chan Ke Za Zhi; 2008 Nov; 43(11):843-8. PubMed ID: 19087569
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
4. Estrogen receptor beta--an independent prognostic marker in estrogen receptor alpha and progesterone receptor-positive breast cancer?
Maehle BO; Collett K; Tretli S; Akslen LA; Grotmol T
APMIS; 2009 Sep; 117(9):644-50. PubMed ID: 19703124
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Hormone Replacement Therapy and Survival in Women with Ovarian Cancer.
Ji E; Kim K; Lee B; Hwang SO; Lee HJ; Lee K; Lee M; Kim YB
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804864
[TBL] [Abstract][Full Text] [Related]
6. Hormone Replacement Therapy After Oophorectomy and Breast Cancer Risk Among BRCA1 Mutation Carriers.
Kotsopoulos J; Gronwald J; Karlan BY; Huzarski T; Tung N; Moller P; Armel S; Lynch HT; Senter L; Eisen A; Singer CF; Foulkes WD; Jacobson MR; Sun P; Lubinski J; Narod SA;
JAMA Oncol; 2018 Aug; 4(8):1059-1065. PubMed ID: 29710224
[TBL] [Abstract][Full Text] [Related]
7. Sex Steroid Hormone Receptor Expression Affects Ovarian Cancer Survival.
Jönsson JM; Arildsen NS; Malander S; Måsbäck A; Hartman L; Nilbert M; Hedenfalk I
Transl Oncol; 2015 Oct; 8(5):424-433. PubMed ID: 26500033
[TBL] [Abstract][Full Text] [Related]
8. Spatiotemporal changes in mechanical matrisome components of the human ovary from prepuberty to menopause.
Ouni E; Bouzin C; Dolmans MM; Marbaix E; Pyr Dit Ruys S; Vertommen D; Amorim CA
Hum Reprod; 2020 Jun; 35(6):1391-1410. PubMed ID: 32539154
[TBL] [Abstract][Full Text] [Related]
9. The effects of pre-operative menopausal status and hormone replacement therapy (HRT) on sexuality and quality of life after risk-reducing salpingo-oophorectomy.
Tucker PE; Bulsara MK; Salfinger SG; Tan JJ; Green H; Cohen PA
Maturitas; 2016 Mar; 85():42-8. PubMed ID: 26857878
[TBL] [Abstract][Full Text] [Related]
10. Changes in gonadal steroid receptors in the cardinal ligaments of prolapsed uteri: immunohistomorphometric data.
Ewies AA; Thompson J; Al-Azzawi F
Hum Reprod; 2004 Jul; 19(7):1622-8. PubMed ID: 15142996
[TBL] [Abstract][Full Text] [Related]
11. Postoperative hormone replacement therapy for epithelial ovarian cancer patients: a systematic review and meta-analysis.
Li D; Ding CY; Qiu LH
Gynecol Oncol; 2015 Nov; 139(2):355-62. PubMed ID: 26232517
[TBL] [Abstract][Full Text] [Related]
12. ERβ overexpression results in endocrine therapy resistance and poor prognosis in postmenopausal ERα-positive breast cancer patients.
Guo L; Zhang YU; Yilamu D; Liu S; Guo C
Oncol Lett; 2016 Feb; 11(2):1531-1536. PubMed ID: 26893775
[TBL] [Abstract][Full Text] [Related]
13. Serum estrogen receptor beta mediated bioactivity correlates with poor outcome in lung cancer patients.
Lim VW; Lim WY; Zhang Z; Li J; Gong Y; Seow A; Yong EL
Lung Cancer; 2014 Aug; 85(2):293-8. PubMed ID: 24951317
[TBL] [Abstract][Full Text] [Related]
14. Hormone replacement therapy and prognosis in ovarian cancer patients.
Hein A; Thiel FC; Bayer CM; Fasching PA; Häberle L; Lux MP; Renner SP; Jud SM; Schrauder MG; Müller A; Wachter D; Strehl J; Hartmann A; Beckmann MW; Rauh C
Eur J Cancer Prev; 2013 Jan; 22(1):52-8. PubMed ID: 22694828
[TBL] [Abstract][Full Text] [Related]
15. Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival.
Lenhard M; Tereza L; Heublein S; Ditsch N; Himsl I; Mayr D; Friese K; Jeschke U
BMC Cancer; 2012 Nov; 12():553. PubMed ID: 23176303
[TBL] [Abstract][Full Text] [Related]
16. The safety of postoperative hormone replacement therapy in epithelial ovarian cancer patients in China.
Wen Y; Huang H; Huang H; Wu M; Shen K; Pan L
Climacteric; 2013 Dec; 16(6):673-81. PubMed ID: 23710587
[TBL] [Abstract][Full Text] [Related]
17. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological characteristics of breast cancers in post-menopausal women receiving hormone replacement therapy for menopause.
Salmon RJ; Ansquer Y; Asselain B; Languille O; Lesec G; Remvikos Y
Oncol Rep; 1999; 6(3):699-703. PubMed ID: 10203618
[TBL] [Abstract][Full Text] [Related]
19. Association of regimens of hormone replacement therapy to prognostic factors among women diagnosed with breast cancer aged 50-64 years.
Daling JR; Malone KE; Doody DR; Voigt LF; Bernstein L; Marchbanks PA; Coates RJ; Norman SA; Weiss LK; Ursin G; Burkman RT; Deapen D; Folger SG; McDonald JA; Simon MS; Strom BL; Spirtas R
Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1175-81. PubMed ID: 14652277
[TBL] [Abstract][Full Text] [Related]
20. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
